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Introduction 
Decline in physical function can be anticipated in life-limiting illnesses. Understanding how 
and when the patients’ function will change is critical in assisting patients receiving palliative 
care and their families meaningfully engage in decision making about their care. It will also 
enable better planning of health services. For patients, knowledge of functional decline can 
help them consider options regarding the place of care and how future care needs can be 
met best. Family members may find such information important in deciding when to take 
leave from work or in negotiating care arrangements and plans within the family. Better 
understanding the trajectories of functional decline will help health professionals provide 
What is already known about the topic 
• Functional decline can be anticipated for people with life limiting illnesses. 
• Trajectories of functional decline differ in shapes and patterns. 
• Understanding patterns of functional decline has implications for patient care and 
design of responsive health services. 
What this paper adds 
• This prospective study identifies two contemporary trajectories of functional decline 
for patients receiving specialist palliative care in the last 120 days of life. 
• Precipitous deterioration in functional decline for cancers, solid organ failure and 
cardiovascular disease occurs as cohorts of patients approach an AKPS of 40. 
• The pattern of functional decline for the neurological and dementias cohorts is 
flatter, showing a prolonged period of low function. 
Implications for practice, theory or policy 
• Study findings highlight that different types of care responses and resource allocation 
may be needed at different time points in different trajectories. 
• This may require rapid mobilisation of carer support and modification of care plans 
preceding a precipitous functional decline (Trajectory 1).  
• Extended periods of support to maintain patient function and support carers is 
required for those with a prolonged slow rate of functional decline (Trajectory 2). 
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information to their patients to optimise their function and quality of life[1-4] as well as assist 
us design more responsive health services.[3, 5-9] 
 Trajectories of functional decline differ in shapes and patterns.[10] Four trajectories 
developed in the early 2000s continue to inform current economic and health service 
delivery: Sudden death: precipitous unexpected demise; Cancer: decline in the last 3 months 
after a variable plateau period; Organ failure: saw tooth pattern (chronic remitting and 
relapsing diseases) and Other: which includes ‘unclassified’ and ‘dwindling’.[2, 9] However, as 
treatments change in late-stage disease and as co-morbidities are better managed, people 
live for longer, extending and potentially changing the disease trajectories of patients 
today.[5, 11-13] Trajectories of functional decline are therefore dynamic and need to be 
reviewed as clinical care evolves. Further, trajectories must be also relevant to diagnosis and 
the country in which care is provided when planning health service delivery around 
theoretical models of functional decline.5, 13 There is an imperative for us to understand 
better current patterns of functional decline. This will inform the way we respond to care 
needs and health service and resource implications and will also provide a baseline to aid 
understanding of the effects of interventions to manage functional decline. 
 The aim of this study was to describe the trajectory of functional decline at the end-of-
life in an Australian palliative care population, separated into diagnosis based cohorts. Of 
particular interest was the identification of time points associated with a significant change 
in the rate of functional decline.  
 
Methods 
Study design and setting 
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This was a consecutive cohort study of prospectively collected data using the Palliative Care 
Outcomes Collaboration (PCOC) longitudinal database. PCOC is a national program that 
collects voluntarily submitted clinical data from specialist palliative care services. These data 
are used for evaluating patient outcomes at a service level and benchmarking between 
services. PCOC has been approved by the Human Research Ethics Committee of the 
University of Wollongong (approval ID: HE06/045). Data collection was of routine clinical 
data de-identified and aggregated, and separate consent was not required. Using death as 
the anchor time point, data from the preceding four months were examined. 
Participants and variables 
 This analysis included all patients with at least one recorded Australia-modified 
Karnofsky Performance Status (AKPS) score who died in the care of 115 palliative care 
services between 1st January 2013 – 31st December 2015. Data were integrated for patients 
cared for by multiple palliative care services in community and inpatient settings, using a 
statistical linkage key in combination with the patient’s residential postcode. Patients are 
allocated to a PCOC diagnostic group based on the principal life limiting illness that 
necessitates a referral to palliative care. While many patients will have comorbidities and 
multimorbidity, this is not captured in PCOC data. Patients were grouped into five diagnostic 
cohorts: cancers; solid organ failure; neurological conditions; Alzheimer’s Disease (AD) and 
other dementias (hereon known as dementias); cardiovascular disease; other and unknown. 
Cancer, solid organ failure and dementias1 were selected based on cohorts frequently 
referred to in other trajectory studies.2, 4, 14 There are some indications that those with 
neurological disorders and cardiac disease may have different care needs and a longer and 
more variable progress, making an investigation of the trajectories of these groups useful in 
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a large cohort sample.15-17 Other and unknown were not included in the modelling due to 
the range of diagnoses and small numbers.  
 Functional status was measured using the Australia-modified Karnofsky Performance 
Status scale, an 11 point scale that reflects functional independence (100 – fully functional; 
0 – dead). A person with an AKPS score of 40 would be in bed more than 50% of the time. 
People requiring considerable assistance with self-care and as well as frequent medical care 
would score an AKPS of 50. Those requiring minimal assistance with self-care on occasion 
would score an AKPS of 60.18 Recommended frequency of AKPS assessments is daily or at 
each clinical contact (i.e. assessment frequency may vary according to the clinical setting 
e.g. inpatient, hospital consultation and community settings and access to the patient).[19] 
However, AKPS scores are only submitted to PCOC at change of Phase. Phases of care relate 
to the patient and are defined as ‘stable’, ‘unstable’, ‘deteriorating’, and ‘terminal’. They 
have been found to be a reliable measure that can be used to plan responsive clinical care. 
20 
Statistical methods 
All data points were included and no data were imputed. Cohort characteristics were 
reported using descriptive statistics. All longitudinal analysis of trajectory of function were 
undertaken using a segmented (piece wise) regression. The variable of interest was change 
in AKPS score over time using the number of days before death as the longitudinal 
component. Segmented (piece wise) regression was used to identify time points prior to 
death associated with significant changes in the rate of functional decline (slope) at the 
group level in each diagnostic cohort.21 Analysis examined the changes occurring on average 
to the trajectories of the five cohorts over time. An algorithm was written in R22 using the 
‘segmented’ package21, 23 to compare models with between one and five change points. The 
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number of change points and resulting segmented regression model that best describes the 
trajectory of functional decline was determined using the Bayesian Information Criterion 
(BIC). Differences in trajectories for males / females and different age groups were 
investigated visually by employing Loess Smoothing.  
Sensitivity analyses 
There is no agreed national or international criteria for referral to specialist palliative care. 
As such, late referrals have the potential to influence the modelled trajectories. To 
investigate this, a sensitivity analysis was performed by rerunning the segmented regression 
model algorithm, after removing patients referred less than 14 days before death from the 
analysis.   
Results 
Data were collected from 55,954 patients cared for in hospices, hospitals and at home with 
237,544 AKPS data points. The distribution of diagnoses (Table 1) and the characteristics of 
patients in each cohort (Table 2) demonstrated expected differences in age with the 
dementias cohort the oldest (mean 84.8, sd 8.7). It also had the highest proportion of 
females (60.4%) but the smallest number of observations (1,336 patients and 2,442 
assessments). The cancers cohort had the largest number of observations (39,783 patients 
and 190,567 assessments), were the youngest (mean 71.6, sd 13.5) and a lower proportion 
of females (45.0%). 
Table 1. Summary of diagnostic cohorts and related PCOC diagnoses. 
 
Diagnostic cohort PCOC diagnosis Patients 
N=53,458 
Assessments 
N=227,872 
Cancers  
 
Malignant – not further defined        517          2,150  
Bone and soft tissue cancer         564          2,679  
Breast cancer     2,769        14,178  
Central nervous system cancer         845          4,468  
Colorectal cancer     4,615        22,780  
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Other Gastro-intestinal cancer     3,802        17,889  
Haematological cancer     2,496          9,672  
Head and neck cancer     2,234        10,370  
Lung cancer     8,830        42,448  
Pancreas cancer     2,685        12,848  
Prostate cancer     2,364        12,951  
Other urological cancer     1,726          8,390  
Gynaecological cancer     1,883        10,068  
Skin cancer     1,627          7,697  
Unknown primary cancer     1,185          4,804  
Other primary malignancy     1,641          7,175  
 Total 
% of study 
39,783 
74.4 
190,567 
83.6 
    
Solid organ failure  End stage kidney disease     1,306          3,922  
 Respiratory failure 1,857         5,986  
 End stage liver disease        500          1,468  
 Multiple organ failure        375             645  
 Total 
% of study 
4,038 
7.6 
12,021 
5.3 
    
Neurological conditions Stroke     1,069          1,869  
 Motor Neurone Disease        344          1,729  
 Other neurological disease     1,087          3,102  
 Total 
% of study 
2,500 
4.7 
6,700 
2.9 
    
Cardiovascular disease Cardiovascular disease Total 
% of study 
    2,369 
4.4  
        6,584 
2.9  
    
Alzheimer's disease 
/Dementia 
Alzheimer’s dementia        504             954  
Other dementia        832          1,488  
 Total 
% of study 
1,336 
2.5 
2,442 
1.1 
    
Other Non Malignant – not further defined        389             983  
HIV/AIDS          22             130  
Diabetes and its complications          60             211  
Sepsis        425             817  
Other non-malignancy     2,221          6,401  
 Total 
% of study 
3,117 
5.8 
8,542 
3.7 
    
Unknown Unknown Total 
% of study 
315 
0.6 
1,016 
0.4 
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Table 2. Characteristics of the five diagnostic cohorts. 
 Cancer  
 
(N = 39,783) 
Solid organ  
failure 
(N = 4,038) 
Neurological 
conditions 
(N = 2,500) 
Cardiovascular 
disease 
(N = 2,369) 
Alzheimer’s & 
Dementia 
(N = 1,336) 
Entire cohort 
 
(N = 53,458) 
       
       
Female (%) 45.0 43.3 54.1 49.5 60.4 46.5 
       
Born in Australia (%) 64.9 63.8 63.7 62.7 59.0 64.5 
       
English speaking (%) 90.7 88.5 87.6 88.3 85.9 90.1 
       
Age at death       
   Mean 71.6 77.6 77.5 83.2 84.8 73.7 
   SD 13.5 12.4 14.5 10.8 8.7 13.9 
   Median 73 80 81 86 86 76 
   Range 0 - 109 0 - 110 0 - 104 0 - 104 35 - 107 0 - 110 
       
Place of death (%)       
   Hospital 71.0 72.9 71.3 67.2 38.6 71.0 
   Home 19.7 17.3 12.6 18.1 16.2 19.7 
   Residential aged care 6.8 7.6 13.4 12.2 44.5 6.8 
   Community, not specified 2.4 2.2 2.7 1.9 0.7 2.4 
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Trajectory patterns 
The stacked bar charts in the left hand panel of Figure 1 show the distribution of AKPS 
scores each week prior to death. They demonstrate that function declines for all cohorts 
as patients get closer to death. The functional levels of the  ‘Alzheimer’s Disease and 
other dementia’ group is lower than cancer in the weeks before death with AKPS scores 
of 10 and 20 common in 10+ weeks from death. Cancers have the highest proportion of 
60 - 100 AKPS scores. 
Rate of functional decline and final change points 
Table 3 summarises the results of the segmented regression models. The right hand 
panel of Figure 1 plots the segmented regression lines and the average daily AKPS scores 
for each of the 120 days prior to death.  In the cancers cohort, the segmented 
regression algorithm found that a four change point model best described the trajectory 
of functional decline at the group level. At 120 days prior to death, the modelled 
average AKPS was 55.6. Function is declining for the entire period, with significant 
changes in function at 43.2, 15.8, 8.0 and 3.3 days prior to death (change points in the 
model).  The most rapid decline in function occurs during the last three days of life, with 
a decrease in AKPS of 3.82 on average each day. At 3.3 days prior to death, the mean 
AKPS is 28.9 which decreases to a mean AKPS of 16.3 on the day that the patient died).  
Similar patterns were seen in the other four cohorts, with the rate of functional decline 
increasing at each of the identified change points. Of note, the cancers, solid organ 
failure and cardiovascular cohorts started from a higher AKPS four months preceding 
death. Decline in function is gradual, accelerating more rapidly the closer the patient 
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gets to death. By contrast, the neurological and dementias cohorts demonstrated the 
slowest rate of functional decline and had a lower AKPS at 4 months (< 40) preceding 
death.  
Variability in trajectory means 
Results from the sensitivity analyses are included in Table 3. Models with the same 
number of change points at similar times prior to death were obtained for the cancers 
and neurological conditions cohorts. The algorithm found that a simpler model with a 
single change point provided the best fit in the decline in average daily AKPS for the 
dementias and cardiovascular disease cohorts. The sensitivity analysis shows a more 
gradual decline for the final slopes of the models, however, the change points are also 
further away from death.  
Results from the Loess Smoothing used to investigate differences between age 
groups and between males and females are included in Figure 2. [Insert Figure 2].  The 
results do not vary greatly for age or sex as the trajectories in each plot are similar.
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Table 3. Results of the segmented regression models and sensitivity analyses for each of the five cohorts. 
Estimate (standard error) 
 Cancers  Solid organ  
failure 
Cardiovascular 
disease 
Alzheimer’s & 
dementia 
Neurological 
conditions 
Full model      
      
N 138,711 9,575 5,373 2,227 5,095 
      
Model coefficients      
      
Change point (days)a      
4 (further from death) 43.2 (1.292) - - - - 
3 15.8 (0.492) - - - - 
2 8.0 (0.335) 11.3 (0.460) 15.0 (1.135) 22.8 (2.699) 53.6 (6.0) 
1 (closer to death) 3.3 (0.098) 2.7 (0.331) 4.7 (0.405) 4.5 (0.775) 13.9 (0.905) 
      
Rate of functional decline (slope)b      
5 (further from death) 0.08 (0.010) - - - - 
4 0.26 (0.050) - - - - 
3 0.78 (0.079) 0.12 (0.093) 0.10 (0.103) 0.05 (0.080) 0.00 (0.040) 
2 1.56 (0.092) 1.52 (0.287) 0.86 (0.206) 0.55 (0.249) 0.21 (0.062) 
1 (closer to death) 3.85 (0.069) 3.44 (0.287) 2.77 (0.178) 1.65 (0..237) 1.07 (0.053) 
      
Average AKPS at death (intercept)c 16.30 (0.125) 15.62 (0.362) 15.71 (0.382) 13.87 (0.541) 14.39 (0.276) 
      
      
      
Sensitivity analysisd     
      
N 104,135 4,779 2,468 730 2,346 
      
Model coefficients      
      
Change pointsa      
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4 (further from death) 46.8 (1.659) - - - - 
3 18.4 (0.424) - - - - 
2 7.6 (0.287) 18.3 (1.915) - - 59.8 (8.213) 
1 (closer to death) 2.5 (0.162) 6.1 (0.628) 8.5 (0.565) 19.9 (2.181) 12.6 (1.558) 
      
Rate of functional decline (slope)b      
 5 (further from death) 0.08 (0.011) - - - - 
4 0.23 (0.031) - - - - 
3 0.78 (0.083) 0.11 (0.113) - - -0.01 (0.046) 
2 1.85 (0.169) 0.57 (0.219) 0.11 (0.184) 0.07 (0.094) 0.17 (0.123) 
1 (closer to death) 3.80 (0.151) 2.34 (0.188) 2.18 (0.184) 0.74 (0.091) 0.96 (0.120) 
      
Average AKPS at death (intercept)c 15.98 (0.201) 18.44 (0.595) 17.83 (0.740) 16.23 (0.940) 17.68 (0.713) 
      
 
a The change points describe the number of days prior to death where there is a significant change in the rate of functional decline.  
b The model slope is rate of functional decline (i.e. the decrease in average AKPS for each day closer to death). Slope 1 indicates the 
rate of rate of functional decline in the period just prior to death (the far right on Figure 1). 
c The model intercept is the average AKPS on the day that the patient died. 
d The sensitivity analysis describes the results obtained after re-running the algorithm with late referrals (last 14 days) removed from 
the analysis.  
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Discussion 
The largest trajectory study of its kind internationally, this prospective cohort study sought 
to map the shape and pattern of functional decline trajectories at the end-of-life by 
diagnosis in an Australian palliative care population.  
Significance of the findings 
This study identifies two simplified trajectories of functional decline for five pre-identified 
patient cohorts in the last four months of life, based on the mean AKPS scores 120 days out 
from death; Trajectory 1: Cancer, solid organ failure and cardiovascular disease and 
Trajectory 2: Dementias and neurological conditions. This study builds on previous findings 
that identify a rapid decline in function in the last month of life for a range of diagnostic 
cohorts such as cancer, solid organ failure and frailty.1,2,13,14,24 These prospectively collected 
data mirror some longer prospective2,24 and retrospective1,25 trajectory studies for cancer, 
organ failure,2,13,14 and frailty/dementia.2,12,14 Data show there are rapid periods of decline 
in the last 14 – 22 days of life for all diagnostic cohorts, with the average AKPS score 
dropping by 15 – 26 points.  
Study findings also codify the tipping points in the slope or rate of functional decline 
that enable family and health professionals to plan care more proactively for end stage 
care.26-28 Precipitous deterioration in functional decline for cancers, solid organ failure and 
cardiovascular disease (Trajectory 1) occurs once cohorts of patients approach an AKPS of 
40. A threshold of an AKPS of 40 indicates the need for a rapid increase in caregiver support, 
particularly for people living in the community and modification of care plans as patients 
move towards the terminal phase of care.19 
 The pattern of functional decline of the neurological and dementias cohorts (Trajectory 
2) is flatter, showing a prolonged period of low function. The trajectory for the dementia 
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group is consistent with an earlier study which found higher rates of cognitive decline 
correlated with earlier functional decline, and higher and prolonged rates of functional 
impairment for the frail elderly with cognitive decline.3 This has important ramifications for 
resource allocation and is particularly important when planning supports for community-
dwelling patients and their caregivers as prolonged low AKPS scores indicate substantial 
care is required for an extended time.29 
 Recognition that different diseases have different trajectories and decline points  
highlights the need for potentially different approaches to patient, carer and family support. 
When functional decline is prolonged for patients who choose to die at home, we need to 
consider how to maintain or enhance patient function and caregiver health at this time.29,30 
It may indicate the need for increased allied health care to support patients and carers 
manage the ramifications of functional decline for this sustained period of functional 
dependency. The starting AKPS scores (mean of 37.2 dementias and 55.7 for cancers) 
demonstrate the intensity of support and care needs of this whole cohort at 120 days 
preceding death. Support prior to this time is also indicated given correlations between 
cognitive and functional decline.3 
 Understanding patterns of functional decline can inform the planning and delivery of 
responsive health care to those we cannot cure but sustain with medical and health 
interventions.6,28 However, as with earlier trajectory studies that continue to inform 
development of health care services nearly 20 years after their publication,1,2 these 
trajectories need to be considered within a changing health care context. As we gather a 
more sophisticated understanding of the interplay of clinical interventions on life 
expectancy, quality of life and functional decline, the shapes of the trajectories may well 
change. All of these considerations will influence the design, availability and funding of care 
and service delivery in the future.  
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Strengths and limitations  
A strength of the present study is that it utilised prospective, point-of-care data collection in 
contrast to other studies that employed a retrospective approach.1,3,12,25,31 Earlier trajectory 
studies relied on less rigorous methods to map functional decline such as retrospective 
proxy recall1,25 and the use of non-standardised assessments.1-3,11,25 This study employed the 
AKPS, a standardised assessment tool to record functional status18 and data were drawn 
from an Australian longitudinal palliative care database, PCOC. More recent trajectory 
studies have employed standardised measures to assess end of life functional change over 
time.5,12,13,24 This will allow for comparison of trajectories across diagnoses and countries. As 
noted this is the largest trajectory study of its kind. Earlier trajectory study cohorts range in 
size from < 100,5,13,31 <1000,3,11,14 < 50001,2,25 to <11,000.12,24  While a prospective, point-of-
care data collection was employed in this study, data was examined retrospectively from 
date of death. Therefore, results must be considered in this light. They inform our 
understanding about shapes of trajectories and offer considerations for service planning but 
should not be used prescriptively to make decisions about individual patient care.   
Several factors may have influenced the shape of the two simplified trajectories. 
Approximately 80% of patients of all patients who receive specialist palliative care and 
12.4% of all Australian deaths, including sudden deaths were captured in PCOC data sets in 
2016.32 Only those people referred to palliative care and likely to have advanced disease 
were included in this dataset. As there are no universal criteria for referral to palliative care, 
people with life limiting illnesses who are not referred to palliative care are not included. 
Those with non-malignant disease such as Alzheimer’s Disease or Motor Neurone Disease 
(MND) are more likely to be referred when the disease is significantly advanced so may have 
presented with an initial lower AKPS. Approximately one third of the Australian population 
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are living in residential aged care at the time of their death.33 Numbers of women in 
residential aged care in Australia exceed those of men (two thirds:one third) as they tend to 
live longer.34 This longevity is also associated with higher care needs. The lower AKPS scores 
of women with dementia at 120 days may reflect that they are already receiving support 
through residential aged care and are only likely to be referred at a lower functional level. It 
is likely that people with chronic neurological conditions such as MND will be linked with 
other health care supports at diagnosis which may delay or replace referral to palliative 
care. The precipitous decline of the cancers, solid organ failure and cardiovascular disease 
may in part be due to higher starting AKPS scores preceding death, therefore opportunity to 
fall further. Differences in cohort sizes, both the number of patients and occasions of 
assessment, may be also be responsible for variability in the trajectory means. Disease 
process and sampling times are not independent. Assessment occasions may be dependent 
on disease process such as symptom exacerbations. This may have led to higher numbers of 
AKPS assessments for the cancer cohort and lower assessment numbers for the slower 
progressing diseases such as dementia and MND. Further, they were not collected 
systematically at predetermined times, rather at changes in ‘phase of care’ as described in 
methods as care is delivered.  
 A key finding for clinical practice is the tipping point of an AKPS approaching 40 for 
cancers, solid organ failure and cardiovascular disease. This is significant if functional decline 
is used as a prognostic indicator as it will inform and enable responsive service provision. 
This tipping point gives a targeted window of time when health clinicians, patients and 
families can prepare for the precipitous period of decline. It is important to note however, 
that this is not the only time in disease trajectory that requires targeted interventions and 
care. A second key finding is the flatter trajectory for people with dementias and 
neurological diseases. It identifies the significant ongoing functional care needs that extend 
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for several months preceding the rapid decline.15 Recent studies suggest that specialist 
palliative care interventions can reduce hospitalisations and support patients to die at 
home.28, 35  
 Supporting functional and end-of-life needs of burgeoning numbers of an ageing and 
frail population living in the community with multiple physical and cognitive comorbidities 
requires a targeted approach to care and care interventions. While details about 
multimorbidity are not captured in PCOC data, examination of the impact of increased 
symptom burden and care needs associated with the number and combinations of 
morbidities is an important area for future research given the prevalence of comorbidity 
and multimorbidity in palliative care populations.  
Conclusion 
This paper provides an update and examination of contemporary trajectories of functional 
decline by diagnosis for patients receiving specialist palliative care. It identifies two 
trajectories of functional decline and significant changes in slope or rate of functional 
decline for five pre-identified patient cohorts. It confirms the cancer trajectory, suggesting a 
sustained level of function and a relatively rapid decline to death. It identifies a tipping point 
of an AKPS approaching 40 approximately two weeks before death for cancer, solid organ 
failure cardiovascular disease cohorts which precedes a precipitous decline. This presents an 
opportunity for planning a timely and considered response to patient’s precipitous decline 
and imminent death. It also identifies an extended low level of function with a more gradual 
decline for dementia and neurological cohorts. This suggests patient and caregivers may 
require additional supports to manage functional decline earlier in the disease trajectory. 
Study findings highlight that different types of care responses may be needed at different 
time points for different trajectories. This speaks to the importance of understanding the 
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care needs of different cohorts and the need for policy response to inform appropriate 
health care resource allocation.  
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